Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
AstraZeneca Vaccine: Study of AZD1222 for the Prevention of COVID-19 in Adults (Bronx)
Sponsor:AstraZeneca
Enrolling:Male and Female Patients
Study Length:24 Months
Clinic Visits:7
Minimum Age:18 years old
IRB Number:AAAT2402
U.S. Government ID:NCT04516746
Contact: Logan Posey: 347-590-7280 / lp2907@cumc.columbia.edu
Additional Study Information:

The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.

This study is closed
Investigator
Jessica Justman, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Logan Posey
Email: lp2907@cumc.columbia.edu
Phone: 347-590-7280